Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Equity Ratio: 2009-2022

Historic Equity Ratio for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Sep 2022 value amounting to -0.09.

  • Avadel Pharmaceuticals' Equity Ratio fell 122.78% to -0.09 in Q3 2022 from the same period last year, while for Sep 2022 it was -0.09, marking a year-over-year decrease of 122.78%. This contributed to the annual value of 0.32 for FY2021, which is 39.23% down from last year.
  • Avadel Pharmaceuticals' Equity Ratio amounted to -0.09 in Q3 2022, which was down 304.55% from -0.02 recorded in Q2 2022.
  • In the past 5 years, Avadel Pharmaceuticals' Equity Ratio ranged from a high of 0.53 in Q2 2020 and a low of -0.19 during Q4 2019.
  • Over the past 3 years, Avadel Pharmaceuticals' median Equity Ratio value was 0.37 (recorded in 2021), while the average stood at 0.31.
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 1,419.88% in 2019, then surged by 597.27% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.01 in 2018, then plummeted by 1,419.88% to -0.19 in 2019, then soared by 370.05% to 0.52 in 2020, then crashed by 39.23% to 0.32 in 2021, then slumped by 122.78% to -0.09 in 2022.
  • Its last three reported values are -0.09 in Q3 2022, -0.02 for Q2 2022, and 0.25 during Q1 2022.